CPRX Catalyst Pharmaceuticals
- 14.990
- +0.270+1.83%
Catalyst Pharmaceuticals News
Recent 3.3% Pullback Isn't Enough to Hurt Long-term Catalyst Pharmaceuticals (NASDAQ:CPRX) Shareholders, They're Still up 366% Over 5 Years
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well, when investors win, they can win big. Just think about the savvy investors who
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
20 Companies Screened for Quality in a Cheap -2-
CarGurus Inc. Class A CARG 13.9% 0.0% 28.5% 4.8% 12.0% Inter
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Compa
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Is Largely Controlled by Institutional Shareholders Who Own 65% of the Company
Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Share Price Matching Investor Opinion
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) price-to-earnings (or "P/E") ratio of 26.1x might make it look like a strong sell right now compared to the market in the United States, where around hal
Catalyst Pharmaceuticals(CPRX.US) Director Sells US$392K in Common Stock
$Catalyst Pharmaceuticals(CPRX.US)$ Director Tierney David S sold 25,000 shares of common stock on Apr 8, 2024 at an average price of $15.68 for a total value of $392K.Source: Announcement What is sta
Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing
David S Tierney, Director, on April 08, 2024, sold 25,000 shares in Catalyst Pharmaceuticals (CPRX) for $392,000. Following the Form 4 filing with the SEC, Tierney has control over a total of 348,874
Form 144 | Catalyst Pharmaceuticals(CPRX.US) Director Proposes to Sell 391.82K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 8, $Catalyst Pharmaceuticals(CPRX.US)$ Director Tierney David S intends to sell 25,000 shares of its common stock on Apr 8, with a total market value of approximately $391.
Jim Cramer Recommends Five Small-cap Health-care Stocks
CNBC's Jim Cramer said he thinks it could be a good year for small-cap health stocks and shared his top health-care picks. "I think 2024 could ultimately be the year that small-cap stocks get their mojo back," he said. "This is a group that went out of style when interest rates soared and they'll work a lot better as rates come down."
Top Buy-rated Stocks and Sell-rated Stocks Within Health Care - Citi
Solid Biosciences Gets FDA Rare Pediatric Disease Status for DMD Therapy
Insider Sell: Chief Compliance/Legal Officer Brian Elsbernd Sells 25,000 Shares of Catalyst ...
Catalyst Pharmaceuticals(CPRX.US) Officer Sells US$411K in Common Stock
$Catalyst Pharmaceuticals(CPRX.US)$ Officer Elsbernd Brian sold 25,000 shares of Common Stock on Mar 27, 2024 at an average price of $16.44 for a total value of $411K.Source: Announcement What is stat
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing
Brian Elsbernd, Chief Compliance and Legal Officer, on March 27, 2024, sold 25,000 shares in Catalyst Pharmaceuticals (CPRX) for $411,000. Following the Form 4 filing with the SEC, Elsbernd has contro
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensi
Form 144 | Catalyst Pharmaceuticals(CPRX.US) Officer Proposes to Sell 411K in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 27, $Catalyst Pharmaceuticals(CPRX.US)$ Officer Elsbernd Brian intends to sell 25,000 shares of its common stock on Mar 27, with a total market value of approximately $411K
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
Analysis
Price Target
No Data
